Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GNVC

GenVec (GNVC) Stock Price, News & Analysis

GenVec logo

About GenVec Stock (NASDAQ:GNVC)

Advanced Chart

Key Stats

Today's Range
$7.19
$7.19
50-Day Range
N/A
52-Week Range
$2.70
$10.44
Volume
N/A
Average Volume
259,136 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Receive GNVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GenVec and its competitors with MarketBeat's FREE daily newsletter.

GNVC Stock News Headlines

Cold virus can hunt down cancer
Huangshan Novel Co Ltd Class A 002014
[INSIDE] Elon’s Next Move Could Send This AI Stock Soaring
Missed Nvidia? This Under-the-Radar AI Stock Could Be Next Musk's AI empire is just beginning — and one overlooked company could be at the center of it all. We reveal everything in this exclusive Memorial Day webinar.
GenVec Stock Hit by Pancreas Study's Details
Early Volume Plays: Novavax, GenVec
GenVec Value Slammed on Drug Failure
See More Headlines

GNVC Stock Analysis - Frequently Asked Questions

GenVec Inc (NASDAQ:GNVC) released its quarterly earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million.

GenVec's stock reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that GenVec investors own include Meta Platforms (META), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), NVE (NVEC), Microbot Medical (MBOT) and Pluristem Therapeutics (PSTI).

Company Calendar

Last Earnings
11/04/2016
Today
5/24/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:GNVC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:GNVC) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners